Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4108740 | 0.84 | CTSB (0.36) | PPARGCTSBMETAP2MEN1KMT2A | |
| SCHEMBL4125812 | 0.82 | ALDH1A1 (0.39) | PPARGCTSBMEN1KMT2ALMNA | |
| SCHEMBL13894902 | 0.82 | CTSB (0.36) | PPARGCTSBMEN1KMT2ALMNA | |
| SCHEMBL4111581 | 0.80 | CSNK2A1 (0.35) | CSNK2A1POLBRAB9AALDH1A1CSNK2A2 | |
| SCHEMBL4492591 | 0.78 | CSNK2A1 (0.34) | CSNK2A1CSNK2A2 | |
| Benzene SCHEMBL4492595 | 0.74 | CSNK2A1 (0.36) | CSNK2A1CSNK2A2 | |
| SCHEMBL4492593 | 0.74 | CSNK2A1 (0.35) | CSNK2A1CSNK2A2 | |
| SCHEMBL14287459 | 0.67 | RAB9A (0.42) | CTSBMETAP2LMNAPOLBTSHR | |
| SCHEMBL14287456 | 0.65 | RAB9A (0.42) | PPARGCTSBMETAP2MEN1KMT2A | |
| SCHEMBL4111647 | 0.64 | ATM (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064214-B1 | Pyrazolo[l,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives useful as protein kinase inhibitors | POLARIS GROUP (TW) | 2013-01-30 | — | — | EP | disclosed |
| US-20090247501-A1 | PROTEIN KINASE INHIBITORS | POLARIS GROUP (TW) | 2009-10-01 | — | — | US | disclosed |
| US-20090247501-A1 | PROTEIN KINASE INHIBITORS | POLARIS GROUP (TW) | 2009-10-01 | — | — | US | disclosed |
| US-20090247501-A1 | PROTEIN KINASE INHIBITORS | POLARIS GROUP (TW) | 2009-10-01 | — | — | US | disclosed |
| EP-2064214-A1 | PYRAZ0L0(L,5-A) (1, 3, 5) TRIAZINE AND PYRAZOLO (1, 5-A) PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | Polaris Group (TW) | 2009-06-03 | — | — | EP | disclosed |
| US-7517882-B2 | Protein kinase inhibitors | POLARIS GROUP (CN) | 2009-04-14 | — | — | US | disclosed |
| US-7517882-B2 | Protein kinase inhibitors | POLARIS GROUP (CN) | 2009-04-14 | — | — | US | disclosed |
| US-7517882-B2 | Protein kinase inhibitors | POLARIS GROUP (CN) | 2009-04-14 | — | — | US | disclosed |
| WO-2008036277-A1 | PYRAZ0L0(L,5-A) (1, 3, 5) TRIAZINE AND PYRAZOLO (1, 5-A) PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | POLARIS GROUP (TW) | 2008-03-27 | — | — | WO | disclosed |
| US-20080070893-A1 | Protein Kinase Inhibitors | POLARIS GROUP (CN) | 2008-03-20 | — | — | US | disclosed |
| US-20080070893-A1 | Protein Kinase Inhibitors | POLARIS GROUP (CN) | 2008-03-20 | — | — | US | disclosed |
| US-20080070893-A1 | Protein Kinase Inhibitors | POLARIS GROUP (CN) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070893-A1 | Protein Kinase Inhibitors | MAP3K15, MAP3K20, MAP3K5 | CSNK2A1 482/4885PPARG 3398/4885SLC29A1 3003/4885 |
| US-20090247501-A1 | PROTEIN KINASE INHIBITORS | MAP3K15, MAP3K20, MAP3K5 | CSNK2A1 482/4885PPARG 3398/4885SLC29A1 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.